<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877837</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001894</org_study_id>
    <nct_id>NCT01877837</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation for Sickle Cell Anemia</brief_title>
  <official_title>Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hackensack Meridian Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will be investigating the use of stem cell transplantation, in related donors,&#xD;
      to cure sickle cell disease. Sickle cell disease is a recessive disorder caused by a point&#xD;
      mutation that results in the substitution of valine for glutamic acid at the sixth position&#xD;
      in the B-chain of hemoglobin. This leads to sickling of the red blood cells under many&#xD;
      conditions, such as hypoxia, dehydration, and hyperthermia. The sickling leads to&#xD;
      vaso-occlusion, which causes irreversible damage in almost all systems in the body, including&#xD;
      the central nervous system (CNS), lungs, heart, bones, eyes, liver, and kidneys.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      1) To determine disease free survival (DFS) at one year after matched sibling transplant&#xD;
      using either bone marrow (BM), peripheral blood stem cells (PBSC), or umbilical cord blood&#xD;
      (UCB) after a conditioning regimen consisting of Alemtuzumab, Fludarabine, and Melphalan in&#xD;
      patients 2-30 y/o&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Overall survival&#xD;
&#xD;
        2. Rate of neutrophil and platelet engraftment for BM vs. UCB&#xD;
&#xD;
        3. Incidence of graft failure&#xD;
&#xD;
        4. Incidence of grade II-IV and grade III-IV acute graft vs host disease (GVHD)&#xD;
&#xD;
        5. Incidence of chronic GVHD&#xD;
&#xD;
        6. Incidence of other transplant complications, such as veno-occlusive disease, central&#xD;
           nervous system (CNS) toxicity, and idiopathic pneumonia syndrome (IPS)&#xD;
&#xD;
        7. Incidence of reactivation of CMV, EBV, adenovirus, BK/JC virus&#xD;
&#xD;
        8. Incidence of invasive fungal disease&#xD;
&#xD;
        9. Time to immune reconstitution via monitoring of lymphocyte subpopulations and&#xD;
           immunoglobulin levels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>1 year</time_frame>
    <description>Primary endpoint:&#xD;
In each group, the DFS at the 1 year endpoint will be estimated using the Kaplan Meier product limit estimator. The frequencies of the events, ie graft failure, will be enumerated and presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Secondary endpoints:&#xD;
Overall survival: The distribution of time to death from any cause will be estimated by Kaplan- Meier product limit function and plotted. The overall survival will be measured from the time of transplant to any death and patients will be followed for 2 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Related donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.&#xD;
1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.&#xD;
Day Treatment&#xD;
-22 Alemtuzumab 3mg IV (test dose)&#xD;
-21 Alemtuzumab 10mg IV&#xD;
-20 Alemtuzumab 15mg IV&#xD;
-19 Alemtuzumab 20mg IV&#xD;
-8 Fludarabine 30mg/m2 IV&#xD;
-7 Fludarabine 30mg/m2 IV&#xD;
-6 Fludarabine 30mg/m2 IV&#xD;
-5 Fludarabine 30mg/m2 IV&#xD;
-4 Fludarabine 30mg/m2 IV&#xD;
-3 Melphalan 140mg/m2 IV&#xD;
-2 Rest Day&#xD;
-1 Rest Day&#xD;
0 Stem Cell Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]&#xD;
b) Medications&#xD;
i.) Alemtuzumab I. Hb S% must be &lt; or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued &gt;48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below</description>
    <arm_group_label>Related donor</arm_group_label>
    <other_name>Alemtuzumab (Campath)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine</description>
    <arm_group_label>Related donor</arm_group_label>
    <other_name>Fludarabine (Fludara)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.&#xD;
II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion.</description>
    <arm_group_label>Related donor</arm_group_label>
    <other_name>Melphalan (Alkeran)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cells</intervention_name>
    <description>Infusion of Hematopoietic Stem Cells</description>
    <arm_group_label>Related donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient Eligibility&#xD;
&#xD;
             1) Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single or double) with a&#xD;
             total TNC dose of greater than 5 x 107/kg recipient weight)&#xD;
&#xD;
               1. Age 2-30&#xD;
&#xD;
               2. Hb SS, S-thal0, S-thal+, SC&#xD;
&#xD;
               3. Evidence of ongoing hemolysis: Hb&lt;10, retic &gt;5%, LDH &gt; 500, TB&gt;2&#xD;
&#xD;
               4. Karnofsky/Lansky score &gt;50&#xD;
&#xD;
               5. LVSF&gt;26% or LVEF&gt;40%&#xD;
&#xD;
               6. DLCO &gt;40% or O2 sat &gt;85% for those patients that can't perform PFTs&#xD;
&#xD;
               7. GFR &gt;70 and serum creatinine &lt; 1.5 * ULN for age&#xD;
&#xD;
               8. ALT and AST &lt; 5 x ULN, direct bilirubin &lt;2 x ULN&#xD;
&#xD;
               9. If the patient has been on chronic transfusion or has a ferritin &gt;1000, liver&#xD;
                  biopsy should be done and show no evidence of bridging fibrosis or cirrhosis&#xD;
&#xD;
          -  Exclusion criteria&#xD;
&#xD;
               1. Evidence of uncontrolled bacterial, viral, or fungal infection within one month&#xD;
                  prior to initiation of the conditioning regimen&#xD;
&#xD;
               2. Pregnant or breastfeeding&#xD;
&#xD;
               3. HIV positive&#xD;
&#xD;
               4. Written informed consent not obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Krajewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack Meridian Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cell transplant</keyword>
  <keyword>Sickle cell</keyword>
  <keyword>Stem cell transplantation</keyword>
  <keyword>Related</keyword>
  <keyword>Unrelated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

